MedTrace Logo

Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes

NCT04307797 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-09-19

No results posted yet for this study

Summary

The study seeks to explore the cardiovascular effects of co-agonism at the glucagon and (glucagon-like peptide-1) GLP-1 receptor. Glucagon and exenatide will be intravenously infused into participants with type 2 diabetes (T2DM). Overall, the aim of the study is to further the investigator's understanding on the role these endogenous substances have on normal cardiac physiology, myocardial energetics and myocardial glucose uptake through a series of PET and MRI imaging studies

Conditions

Interventions

DRUG

0.9% Sodium-chloride

Part A - 0.9% saline infusion during cardiac PET-MRI scan

DRUG

Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min

Part A - exenatide and glucagon infusion during cardiac PET-MRI scan

DRUG

Glucagon 12.5ng/kg/min and 0.9% saline

Part A - Glucagon and 0.9% saline infusion during PET-MRI scan

DRUG

0.9% Sodium-chloride

Part B - 0.9% saline infusion during 7T 31P MRS scan

DRUG

Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min

Part B - exenatide and glucagon infusion during 7T 31P MRS scan

DRUG

Glucagon 12.5ng/kg/min

Part B - Glucagon infusion during 7T 31P MRS scan

Sponsors & Collaborators

  • Antaros Medical

    collaborator INDUSTRY

  • Cambridge University Hospitals NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Ian Wilkinson, MD · University of Cambridge

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-18
Primary Completion
2022-10-07
Completion
2022-10-07

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04307797 on ClinicalTrials.gov